New combo aims to wipe out lingering leukemia cells before they return

NCT ID NCT07148180

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tests whether a new combination of three drugs (tagraxofusp, azacitidine, and venetoclax) can safely eliminate leftover leukemia cells that are not visible under a microscope in adults with acute myeloid leukemia (AML). These hidden cells can cause the cancer to come back. The trial enrolls about 31 people who are already in remission but have measurable residual disease. The goal is to control the disease and prevent recurrence, not to cure it, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.